A second global pivotal trial will test iza-bren in the same NSCLC setting where patri-dxd failed.
ApexOnco Front Page
Recent articles
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
Readout of the delayed Galaxies Lung-201 study is due imminently.
The group reports more data today, while its pivotal Ares trial, in acute graft-versus-host disease, is set to read out in the fourth quarter.
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
Two pancreatic cancer trials will read out this quarter, but after a string of failures with the project they look like a long shot.